{| class="wikitable" style="text-align:center; width:100%;"
!colspan="4" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editors'''
|-
|style="background-color:#F0F0F0; width: 15%"|[[File:SeemaNagpal.jpg|frameless|upright=0.3|center]]
|style="width:35%" |<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Palo Alto, CA</big>
|style="background-color:#F0F0F0; width: 15%"|[[File:Jcvillasboas.jpg|frameless|upright=0.3|center]]
|style="width:35%" |<big>[[User:Jcvillasboas|J.C. Villasboas Bisneto, MD]]<br>Rochester, MN</big>
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==BSH==
*'''2018:''' Fox et al. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.15661 Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma]

==EANO==
*'''2015:''' Hoang-Xuan et al. [http://www.zora.uzh.ch/id/eprint/114449/ Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology]

==[http://www.esmo.org/ ESMO]==
*'''2016:''' Vitolo et al. [http://annonc.oxfordjournals.org/content/27/suppl_5/v91.full.pdf+html Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/27377716 PubMed]

==GELTAMO==
*'''2016:''' Peñalver et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286932/ Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf NCCN Guidelines - Central Nervous System Cancers]

=Prophylaxis=
==HiDAC {{#subobject:75c24e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
HiDAC: '''<u>Hi</u>'''gh '''<u>D</u>'''ose '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine)
===Regimen {{#subobject:0258f4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/24/5/1385.long Holte et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: IT treatment was not part of prophylaxis, except that [[Methotrexate (MTX)]] 15 mg IT was allowed at time of diagnostic LP.''
====Preceding treatment====
*[[Diffuse_large_B-cell_lymphoma#R-CHOEP-14|R-CHOEP-14]] x 8
====CNS Prophylaxis====
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV twice per day for 2 days (4 doses)
**Dose reduced to 2000 mg/m<sup>2</sup> for patients aged 60 to 65 years

'''One course'''
====Subsequent treatment====
*[[#Methotrexate_monotherapy|HD-MTX]]
===References===
# Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013 May;24(5):1385-92. Epub 2012 Dec 17. [http://annonc.oxfordjournals.org/content/24/5/1385.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23247661 PubMed]

==Methotrexate monotherapy {{#subobject:e89965|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a5d109|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/24/5/1385.long Holte et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: IT treatment was not part of prophylaxis, except that [[Methotrexate (MTX)]] 15 mg IT was allowed at time of diagnostic LP.''
====Preceding treatment====
*[[#HiDAC|HiDAC]]
====CNS Prophylaxis====
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV continuous infusion over 24 hours

====Supportive medications====
*[[Folinic acid (Leucovorin)]] (dose/frequency not specified) starting at 36 hours

'''One course'''

===References===
# Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013 May;24(5):1385-92. Epub 2012 Dec 17. [http://annonc.oxfordjournals.org/content/24/5/1385.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23247661 PubMed]

=Intrathecal, treatment=
==IT Cytarabine monotherapy {{#subobject:867516|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a436da|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/jco.1999.17.10.3110 Glantz et al. 1999]
|style="background-color:#1a9851"|Phase III (C)
|[[#IT_Cytarabine_liposomal_monotherapy|IT liposomal cytarabine]]
|style="background-color:#d73027"|Inferior ORR
|-
|}
====Chemotherapy====
*[[Cytarabine (Cytosar)]] 50 mg IT twice per week

'''One-month course (8 doses)'''

''Further therapy was given to responders; see text for details.''

===References===
# Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999 Oct;17(10):3110-6. [http://ascopubs.org/doi/full/10.1200/jco.1999.17.10.3110 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10506606 PubMed]

==IT Cytarabine liposomal monotherapy {{#subobject:fbf1d4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c43afb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/jco.1999.17.10.3110 Glantz et al. 1999]
|style="background-color:#1a9851"|Phase III (E)
|[[#IT_Cytarabine_monotherapy_2|IT cytarabine]]
|style="background-color:#1a9850"|Superior ORR
|-
|}
====Chemotherapy====
*[[Cytarabine liposomal (DepoCyt)]] 50 mg IT once every 14 days

'''One-month course (2 doses)'''

''Further therapy was given to responders; see text for details.''

===References===
# Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999 Oct;17(10):3110-6. [http://ascopubs.org/doi/full/10.1200/jco.1999.17.10.3110 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10506606 PubMed]

=Upfront therapy, randomized data=

==CYM {{#subobject:eef91c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CYM: '''<u>CY</u>'''tarabine & '''<u>M</u>'''ethotrexate
===Regimen {{#subobject:5ead03|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61416-1/fulltext Ferreri et al. 2009 (IELSG20)]
|style="background-color:#1a9851"|Randomized Phase II, >20 per arm (E)
|[[#Methotrexate_monotherapy_2|High-dose MTX]]
|style="background-color:#91cf60"|Seems to have superior CRR
|-
|rowspan=2|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext Ferreri et al. 2016 (IELSG32)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (C)
|1. [[#Cytarabine.2C_Methotrexate.2C_Rituximab|Cytarabine, Methotrexate, Rituximab]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#MATRix|MATRix]]
|style="background-color:#d73027"|Inferior CR rate
|-
|}
====Chemotherapy====
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 60 minutes every 12 hours on days 2 & 3
*[[Methotrexate (MTX)]] 500 mg/m<sup>2</sup> IV over 15 minutes, then 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1 (total dose per cycle: 3500 mg/m<sup>2</sup>) 

====Supportive medications====
*As described in Ferreri et al. 2016:
*[[Levoleucovorin (Fusilev)]] 15 mg/m<sup>2</sup> IV every 6 hours for 12 doses, beginning 24 hours after the '''start''' of [[Methotrexate (MTX)]]
**Modifications if MTX level is high 48 hours after the '''end''' of the infusion; see paper for details

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*IELSG20: [[#Whole_brain_irradiation|Whole brain irradiation]], within 4 weeks
*IELSG32: [[#Whole_brain_irradiation|Whole brain irradiation]] versus [[#BCNU.2FTT.2C_then_auto_HSCT|Carmustine & Thiotepa with auto HSCT]]

===References===
# '''IELSG20:''' Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009 Oct 31;374(9700):1512-20. Epub 2009 Sep 18. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61416-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19767089 PubMed]
# '''IELSG32:''' Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May;3(5):e217-27. Epub 2016 Apr 6. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27132696 PubMed]

==Cytarabine, Methotrexate, Rituximab {{#subobject:a4671e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1c6830|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext Ferreri et al. 2016 (IELSG32)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#CYM|Cytarabine & Methotrexate]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#MATRix|MATRix]]
|style="background-color:#fc8d59"|Seems to have inferior CR rate
|-
|}
====Chemotherapy====
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 60 minutes every 12 hours on days 2 & 3
*[[Methotrexate (MTX)]] 500 mg/m<sup>2</sup> IV over 15 minutes, then 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1 (total dose per cycle: 3500 mg/m<sup>2</sup>) 
*[[Rituximab (Rituxan)]] 375  mg/m<sup>2</sup> IV once per day on days -5 & 0

====Supportive medications====
*[[Levoleucovorin (Fusilev)]] 15 mg/m<sup>2</sup> IV every 6 hours for 12 doses, beginning 24 hours after the '''start''' of [[Methotrexate (MTX)]]
**Modifications if MTX level is high 48 hours after the '''end''' of the infusion; see paper for details

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*[[#Whole_brain_irradiation|Whole brain irradiation]] versus [[#BCNU.2FTT.2C_then_auto_HSCT|Carmustine & Thiotepa with auto HSCT]]

===References===
# '''IELSG32:''' Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May;3(5):e217-27. Epub 2016 Apr 6. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27132696 PubMed]

==MATRix {{#subobject:7b7130|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MATRix: '''<u>M</u>'''ethotrexate, '''<u>A</u>'''ra-C (Cytarabine), '''<u>T</u>'''hiotepa, '''<u>Ri</u>'''tu'''<u>x</u>'''imab
===Regimen {{#subobject:278704|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext Ferreri et al. 2016 (IELSG32)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#CYM|Cytarabine & Methotrexate]]
|style="background-color:#1a9850"|Superior CR rate
|-
|2. [[#Cytarabine.2C_Methotrexate.2C_Rituximab|Cytarabine, Methotrexate, Rituximab]]
|style="background-color:#91cf60"|Seems to have superior CR rate
|-
|}
====Chemotherapy====
*[[Methotrexate (MTX)]] 500 mg/m<sup>2</sup> IV over 15 minutes, then 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1 (total dose per cycle: 3500 mg/m<sup>2</sup>) 
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 60 minutes every 12 hours on days 2 & 3
*[[Thiotepa (Thioplex)]] 30 mg/m<sup>2</sup> IV over 30 minutes once on day 4
*[[Rituximab (Rituxan)]] 375  mg/m<sup>2</sup> IV once per day on days -5 & 0

====Supportive medications====
*[[Levoleucovorin (Fusilev)]] 15 mg/m<sup>2</sup> IV every 6 hours for 12 doses, beginning 24 hours after the '''start''' of [[Methotrexate (MTX)]]
**Modifications if MTX level is high 48 hours after the '''end''' of the infusion; see paper for details

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*[[#Whole_brain_irradiation|Whole brain irradiation]] versus [[#BCNU.2FTT.2C_then_auto_HSCT|Carmustine & Thiotepa with auto HSCT]]

===References===
# '''IELSG32:''' Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May;3(5):e217-27. Epub 2016 Apr 6. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27132696 PubMed]

==Methotrexate monotherapy {{#subobject:031ce9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 3500 mg/m<sup>2</sup> {{#subobject:8ce96f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61416-1/fulltext Ferreri et al. 2009 (IELSG20)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#CYM|High-dose MTX & Cytarabine]]
|style="background-color:#fc8d59"|Seems to have inferior CRR
|-
|}
====Chemotherapy====
*[[Methotrexate (MTX)]] 500 mg/m<sup>2</sup> IV over 15 minutes, then 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1 (total dose per cycle: 3500 mg/m<sup>2</sup>) 

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*[[#Whole_brain_irradiation|Whole brain irradiation]], within 4 weeks

===Variant #2, 4000 mg/m<sup>2</sup> {{#subobject:dcc365|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext Thiel et al. 2010 (G-PCNSL-SG-1)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}

''All patients received the same induction regimen; however, the induction regimen was changed after 2006 to [[#Ifosfamide_.26_Methotrexate|high-dose MTX & ifosfamide]].''
====Chemotherapy====
*[[Methotrexate (MTX)]] 4000 mg/m<sup>2</sup> IV over 4 hours once on day 1

'''14-day cycle for 6 cycles'''
====Subsequent treatment====
*Patients with CR: [[#Whole_brain_irradiation|whole-brain irradiation]] versus [[#Observation|no further treatment]]
*Patients with less than CR in the WB-XRT arm: [[#Whole_brain_irradiation_2|salvage whole-brain irradiation]]
*Patients with less than CR in the no-WB-XRT: [[#HiDAC_3|salvage HiDAC]]

===Variant #3, 8000 mg/m<sup>2</sup> {{#subobject:8e0230|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ana.20495/full Herrlinger et al. 2005 (NOA-03)]
|style="background-color:#91cf61"|Phase II
|-
|}

''This was considered a negative trial by the authors and is included here for historical purposes.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 hours once on day 1

'''14-day cycle for 6 cycles'''
====Subsequent treatment====
*Patients intolerant of MTX or not achieving CR after 6 cycles: [[#Whole_brain_irradiation_2|salvage whole-brain irradiation]] versus PCV; see article for details

===Variant #4, 8000 mg/m<sup>2</sup> with renal adjustment {{#subobject:567824|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/21/6/1044.long Batchelor et al. 2003 (NABTT 96-07)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 hours once on day 1
**The full dose of 8000 mg/m<sup>2</sup> was only given if CrCl was at least 100 mL/min/1.73m<sup>2</sup>. For CrCl less than 100 mL/min/1.73m<sup>2</sup>, the dose was reduced by the percentage reduction below 100. For example, a CrCl of 50 mL/min/1.73m<sup>2</sup> would mandate a 50% dose reduction.

'''14-day cycle until CR or a maximum of 8 cycles'''
====Subsequent treatment====
*Patients achieving CR received two more cycles at the same dose and frequency, then [[#Methotrexate_monotherapy_3|methotrexate maintenance]]

===Variant #5, 12,000 mg/m<sup>2</sup> {{#subobject:a12fcc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/18/4/665.long Montemurro et al. 2007 (OSHO-53)]
|style="background-color:#91cf61"|Phase II
|-
|}
''This dosing was intended for patients greater than 60 years old.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 6000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 & 10

'''One course'''
====Subsequent treatment====
*Responders (CR or PR): [[#Bu.2FTT.2C_then_auto_HSCT|Bu/TT, then autologous hematopoietic stem cell transplant]]

===Variant #6, 16,000 mg/m<sup>2</sup> {{#subobject:abcfcc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/18/4/665.long Montemurro et al. 2007 (OSHO-53)]
|style="background-color:#91cf61"|Phase II
|-
|}
''This dosing was intended for patients less than 60 years old.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1 & 10

'''One course'''
====Subsequent treatment====
*Responders (CR or PR): [[#Bu.2FTT.2C_then_auto_HSCT|Bu/TT, then autologous hematopoietic stem cell transplant]]

===References===
# '''NABTT 96-07:''' Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003 Mar 15;21(6):1044-9. [http://jco.ascopubs.org/content/21/6/1044.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12637469 PubMed]
# Herrlinger U, Küker W, Uhl M, Blaicher HP, Karnath HO, Kanz L, Bamberg M, Weller M; Neuro-Oncology Working Group of the German Society. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005 Jun;57(6):843-7. [https://onlinelibrary.wiley.com/doi/10.1002/ana.20495/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15929034 PubMed] content property of [http://hemonc.org HemOnc.org]
# Montemurro M, Kiefer T, Schüler F, Al-Ali HK, Wolf HH, Herbst R, Haas A, Helke K, Theilig A, Lotze C, Hirt C, Niederwieser D, Schwenke M, Krüger WH, Dölken G. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol. 2007 Apr;18(4):665-71. Epub 2006 Dec 21. [http://annonc.oxfordjournals.org/content/18/4/665.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17185743 PubMed]
# '''IELSG20:''' Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009 Oct 31;374(9700):1512-20. Epub 2009 Sep 18. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61416-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19767089 PubMed]
# Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20970380 PubMed]
## '''Update: Abstract:''' Agnieszka Korfel, Eckhard Thiel, Peter Martus, Robert Moehle, Frank Griesinger, Michael Rauch, Alexander Roeth, Bernd Hertenstein, Thomas Fischer, Thomas Hundsberger, Hans-Guenther Mergenthaler, Christian Junghanss, Tobias Birnbaum, Lars Fischer, Kristoph Jahnke, Ulrich Herrlinger, Ludwig Plasswilm, Thomas Naegele, Torsten Pietsch, Michael Weller. G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up. J Clin Oncol 32:5s, 2014 (suppl; abstr 8527) [http://meetinglibrary.asco.org/content/129168-144 link to abstract]
## '''Update:''' Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015 Mar 24;84(12):1242-8. Epub 2015 Feb 25. [http://www.neurology.org/content/84/12/1242.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25716362 PubMed]

=Upfront therapy, non-randomized or retrospective data=

==Ferreri regimen {{#subobject:2e75bb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:b5ef1c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/33/33/3903.full Ferreri et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
To be completed

===References===
# Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, Tarella C, Di Nicola M, D'Arco AM, Doa G, Bruno-Ventre M, Assanelli A, Foppoli M, Citterio G, Fanni A, Mulè A, Caligaris-Cappio F, Ciceri F. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: Final results of a multicenter phase II trial. J Clin Oncol. 2015 Nov 20;33(33):3903-10. Epub 2015 Aug 17. [http://jco.ascopubs.org/content/33/33/3903.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26282634 PubMed]

==Lomustine, Methotrexate, Procarbazine {{#subobject:95c040|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MCP: '''<u>M</u>'''ethotrexate, '''<u>C</u>'''CNU (Lomustine), '''<u>P</u>'''rocarbazine

===Regimen {{#subobject:0caeaa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/20/2/319.long Illerhaus et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lomustine (Ceenu)]] 110 mg/m<sup>2</sup> PO once on day 1
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1, 15, 30
*[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 10

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> (route not specified) every 6 hours beginning 24 hours after start of [[Methotrexate (MTX)]] infusion, continued until clearance

'''45-day cycle for up to 3 cycles'''

===References===
# Illerhaus G, Marks R, Müller F, Ihorst G, Feuerhake F, Deckert M, Ostertag C, Finke J. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009 Feb;20(2):319-25. Epub 2008 Oct 26. [http://annonc.oxfordjournals.org/content/20/2/319.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18953065 PubMed]

==Lomustine, Methotrexate, Procarbazine, Methylprednisolone {{#subobject:c81fd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:d3269c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/21/14/2726.long Hoang-Xuan et al. 2003 (EORTC 26952)]
|style="background-color:#91cf61"|Phase II
|-
|}
''This was the first prospective phase II trial evaluating chemotherapy alone in older patients with PCNSL.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 10, 20
*[[Lomustine (Ceenu)]] 40 mg/m<sup>2</sup> PO once on day 1
*[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Methylprednisolone (Solumedrol)]] as follows:
**Days 1 to 20: 120 mg/m<sup>2</sup> IV or PO every other day 
**Days 20 to 45: 60 mg/m<sup>2</sup> IV or PO every other day

====Intrathecal chemotherapy====
*[[Methotrexate (MTX)]] 15 mg IT (admixed with [[Cytarabine (Cytosar)]]) once per day on days 1, 5, 10, 15
*[[Cytarabine (Cytosar)]] 40 mg IT (admixed with [[Methotrexate (MTX)]]) once per day on days 1, 5, 10, 15

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 25 mg PO every 6 hours for 3 days, initiated 24 hours after IV [[Methotrexate (MTX)]] administrations, and 10 mg PO every 6 hours for 2 days after IT [[Methotrexate (MTX)]] administrations

'''45-day course'''
====Subsequent treatment====
*Patients achieving PR or CR: [[#Lomustine.2C_Methotrexate.2C_Procarbazine_2|Lomustine, methotrexate, procarbazine maintenance]]

===References===
# '''EORTC 26952:''' Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B; European Organization for Research and Treatment of Cancer Brain Tumor Group. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003 Jul 15;21(14):2726-31. [http://jco.ascopubs.org/content/21/14/2726.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12860951 PubMed]

==Methotrexate, then Cytarabine {{#subobject:f24bde|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:1d3fff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/21/22/4151.long Abrey et al. 2003]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy, part 1====
*[[Methotrexate (MTX)]] 3500 mg/m<sup>2</sup> (maximum dose of 7000 mg) IV over 2 hours once on day 1

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 25 mg PO every 6 hours, beginning 24 hours after start of [[Methotrexate (MTX)]], continued for 12 doses or until serum MTX level less than 100 nmol/L

'''14-day cycle for 5 cycles'''

''Patients proceed to part two 72 hours after 5th dose of MTX or once the 5th dose MTX level has cleared:''

====Chemotherapy, part 2====
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV once per day on days 1 & 2

====Supportive medications====
*[[Filgrastim (Neupogen)]] as follows:
**Cycle 1: 10 mcg/kg SC once per day, starting on day 4 and continued until stem cell collection complete
**Cycle 2: 5 mcg/kg SC once per day continued for 2 weeks or until ANC greater than 3000/uL

'''1-month cycle for 2 cycles (Stem cell collection took place after the first cycle)'''
====Subsequent treatment====
*[[#BEAM.2C_then_auto_HSCT|BEAM, then autologous hematopoietic stem cell transplant]]

===References===
# Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. [http://jco.ascopubs.org/content/21/22/4151.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14615443 PubMed]

==Methotrexate, then Cytarabine & Thiotepa {{#subobject:990369|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:e9fd90|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/24/3865.full Illerhaus et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy, part 1====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 hours once per day on days 1, 10, 20

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> every 6 hours, beginning 24 hours after start of [[Methotrexate (MTX)]], continuing until clearance

'''One course'''

''Patients with CR, PR, or SD "with clinical improvement" after the 2nd dose of MTX proceeded to:''
====Chemotherapy, part 2====
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV over 3 hours once per day on days 30 & 31
*[[Thiotepa (Thioplex)]] 40 mg/m<sup>2</sup> (route not specified) once on day 31

'''One course for stem cell mobilization'''
====Subsequent treatment====
*[[#BCNU.2FTT.2C_then_auto_HSCT|BCNU/TT, then autologous hematopoietic stem cell transplant]]

===Variant #2 {{#subobject:92e01d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/93/1/147.long Illerhaus et al. 2008]
|style="background-color:#ffffbe"|Pilot, <20 patients
|-
|}
====Chemotherapy, part 1====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 hours once on day 1

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> every 6 hours, beginning 24 hours after start of [[Methotrexate (MTX)]], continuing until clearance

'''10-day cycle for 2 to 4 cycles, followed by:'''
====Chemotherapy, part 2====
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Thiotepa (Thioplex)]] 40 mg/m<sup>2</sup> (route not specified) once on day 2

'''21-day cycle for 2 cycles (Stem cells are mobilized and collected after the first cycle)'''
====Subsequent treatment====
*[[#BCNU.2FTT.2C_then_auto_HSCT|BCNU/TT, then autologous hematopoietic stem cell transplant]]

===References===
<!-- Presented in part at the 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10-13, 2005. -->
# Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24. [http://jco.ascopubs.org/content/24/24/3865.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16864853 PubMed]
## '''Update:''' Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol. 2012 Oct;23(10):2670-5. Epub 2012 Apr 3. Erratum in: Ann Oncol. 2015 Mar;26(3):608-11. [http://annonc.oxfordjournals.org/content/23/10/2670.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22473593 PubMed]
# Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008 Jan;93(1):147-8. [http://www.haematologica.org/content/93/1/147.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18166803 PubMed]
## '''Update:''' Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol. 2012 Oct;23(10):2670-5. Epub 2012 Apr 3. Erratum in: Ann Oncol. 2015 Mar;26(3):608-11. [http://annonc.oxfordjournals.org/content/23/10/2670.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22473593 PubMed]

==Methotrexate & Rituximab {{#subobject:45f333|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:715330|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940660/ Chamberlain et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: the bounds as described in the paper do not account for the situation where CrCl = 60 mL/min/1.73m<sup>2</sup>.''
====Chemotherapy====
*[[Methotrexate (MTX)]] as follows:
**CrCl greater than 60 mL/min/1.73m<sup>2</sup>: 8000 mg/m<sup>2</sup> IV over 6 hours once on day 1
**CrCl less than 60 mL/min/1.73m<sup>2</sup>: 4000 mg/m<sup>2</sup> IV over 6 hours once on day 1
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 8

'''14-day cycle for 4 to 6 cycles'''
====Subsequent treatment====
*Patients with PR/CR: [[#Methotrexate_monotherapy_3|High-dose methotrexate consolidation]]

===References===
# Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 2010 Jul;12(7):736-44. [http://neuro-oncology.oxfordjournals.org/content/12/7/736.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940660/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20511181 PubMed]

==MPV {{#subobject:245afd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MPV: '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rocarbazine, '''<u>V</u>'''incristine

===Regimen {{#subobject:2cb0c6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2000.18.17.3144 Abrey et al. 2000]
|style="background-color:#91cf61"|Non-randomized
|-
|[http://jco.ascopubs.org/content/20/24/4643.long DeAngelis et al. 2002 (RTOG 93-10)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Methotrexate (MTX)]] 2500 mg/m<sup>2</sup> IV over 2 to 3 hours once on day 1
*[[Procarbazine (Matulane)]] as follows:
**Cycles 1, 3, 5: 100 mg/m<sup>2</sup> PO once per day on days 1 to 7
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2.8 mg) IV once on day 1

====Intrathecal chemotherapy====
*[[Methotrexate (MTX)]] 12 mg IT (via Ommaya) once one week after IV [[Methotrexate (MTX)]] administration

====Supportive medications====
*[[Folinic acid (Leucovorin)]] as follows:
**20 mg PO every 6 hours x 12 doses, beginning 24 hours after IV [[Methotrexate (MTX)]] administration
**10 mg PO every 6 hours x 8 doses, beginning the evening of IT [[Methotrexate (MTX)]] administration
*[[Dexamethasone (Decadron)]] 16 mg PO once per day x 7 days, then 12 mg PO once per day x 7 days, then 8 mg PO once per day x 7 days, then 6 mg PO once per day x 7 days, then 4 mg PO once per day x 7 days, then 2 mg PO once per day x 7 days (starts with first cycle)

'''14-day cycle for 5 cycles'''
====Subsequent treatment====
*[[#Whole_brain_irradiation|Whole-brain irradiation]] 

===References===
# Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000 Sep;18(17):3144-50. [http://ascopubs.org/doi/10.1200/JCO.2000.18.17.3144 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10963643 PubMed]
## '''Update:''' Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006 Oct 1;24(28):4570-4. [http://ascopubs.org/doi/full/10.1200/JCO.2006.06.6910 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17008697 PubMed]
# '''RTOG 93-10:''' DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002 Dec 15;20(24):4643-8. [http://jco.ascopubs.org/content/20/24/4643.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12488408 PubMed]

==MT-R {{#subobject:cc7d83|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MT-R: '''<u>M</u>'''ethotrexate, '''<u>T</u>'''emozolomide, '''<u>R</u>'''ituximab

===Variant #1 {{#subobject:5cf6d6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872318/ Glass et al. 2016 (RTOG 0227)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''This is the MTD of this phase I/II trial; it appears that only a single dose of rituximab was given.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 3500 mg/m<sup>2</sup> IV once per week on weeks 1, 3, 5, 7, 9
*[[Temozolomide (Temodar)]] as follows:
**Weeks 4 & 8: 100 mg/m<sup>2</sup> PO once per day for 5 days
**Other weeks: omitted
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once 3 days prior to first MTX

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 25 mg IV every 6 hours, starting 24 hours after [[Methotrexate (MTX)]], continue until MTX level less than 100 nmol/L 

'''9-week course'''
====Subsequent treatment====
*[[#Whole_brain_irradiation|WB-XRT consolidation]]

===Variant #2 {{#subobject:5df6e6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753699/ Rubenstein et al. 2013 (CALGB 50202)]
|style="background-color:#91cf61"|Phase II
|-
|}

====Chemotherapy====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 hours once on day 1
*[[Temozolomide (Temodar)]] as follows:
**Cycles 1, 3, 5, 7: 150 mg/m<sup>2</sup> PO once per day on days 7 to 11
**Cycles 2, 4, 6: omitted
*[[Rituximab (Rituxan)]] as follows:
**B-cell PCNSL, Cycles 1 to 6: 375 mg/m<sup>2</sup> IV once on day 3
**T-cell PCNSL: omitted

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 100 mg/m<sup>2</sup> IV every 6 hours, start on day 2, continue until MTX level less than 50 nmol/L 

'''14-day cycle for 7 cycles'''
====Subsequent treatment====
*Patients achieving CR or CRu were given one additional cycle of methotrexate & temozolomide, then [[#CYVE|CYVE consolidation]]

===References===
# Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 Sep 1;31(25):3061-8. Epub 2013 Apr 8 [http://jco.ascopubs.org/content/31/25/3061.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753699/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23569323 PubMed]
# Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016 May 10;34(14):1620-5. Epub 2016 Mar 28. [http://jco.ascopubs.org/content/34/14/1620.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872318/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27022122 PubMed]

==MVBP {{#subobject:891647|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MVBP: '''<u>M</u>'''ethotrexate, '''<u>V</u>'''P16 (Etoposide), '''<u>B</u>'''CNU (Carmustine), Methyl'''<u>P</u>'''rednisolone

===Regimen {{#subobject:70497b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html Colombat et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once on day 2
*[[Carmustine (BiCNU)]] 100 mg/m<sup>2</sup> IV once on day 3
*[[Methylprednisolone (Solumedrol)]] 60 mg/m<sup>2</sup> (route not specified) once per day on days 1 to 5

====Intrathecal chemotherapy====
''6 doses total, timing is not specified''
*[[Methotrexate (MTX)]] 20 mg IT (admixed with [[Cytarabine (Cytosar)]] and [[Methylprednisolone (Solumedrol)]])
*[[Cytarabine (Cytosar)]] 50 mg IT (admixed with [[Methotrexate (MTX)]] and [[Methylprednisolone (Solumedrol)]])
*[[Methylprednisolone (Solumedrol)]] 40 mg IT (admixed with [[Cytarabine (Cytosar)]] and [[Methotrexate (MTX)]])

====Supportive medications====
*[[Folinic acid (Leucovorin)]] details not specified

'''2 courses, separated by 21 days'''
====Subsequent treatment====
*Responding patients (CR or PR): cytarabine & ifosfamide for stem cell mobilization, then [[#BEAM.2C_then_auto_HSCT|BEAM, then autologous hematopoietic stem cell transplant]]
*Non-responders: [[#CYVE|Salvage CYVE]]
===References===
# Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16951691 PubMed]

==Nordic Regimen, older patients {{#subobject:1778db|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:eb66bd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380727/ Pulczynski et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}

''This regimen is meant for patients aged 66-75 years.''

====Chemotherapy, A cycles====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 '''of the 1st A cycle only'''
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV once on day 1
*[[Ifosfamide (Ifex)]] 800 mg/m<sup>2</sup> IV once per day on days 2 to 5 '''of the 1st A cycle only'''
*[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup>/day PO on days 2 to 5
*[[Cytarabine liposomal (DepoCyt)]] 50 mg IT once on day 2

====Chemotherapy, B cycles====
*[[Methotrexate (MTX)]] 5000 mg/m<sup>2</sup> IV once on day 1
*[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup>/day PO on days 2 to 5
*[[Cytarabine liposomal (DepoCyt)]] 50 mg IT once on day 2
*[[Cyclophosphamide (Cytoxan)]] 150 mg/m<sup>2</sup> IV once per day on days 2 to 6

====Chemotherapy, C cycles====
*[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup>/day PO on days 3 to 7
*[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV every 12 hours on days 1 & 2
*[[Vindesine (Eldisine)]] 5 mg IV once on day 1

'''21-day cycle for 6 cycles (A, then B, then C, then A, then B, then C)'''
====Subsequent treatment====
*[[#Temozolomide_monotherapy|Temozolomide maintenance]]

===References===
# Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli UM. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica. 2015 Apr;100(4):534-40. Epub 2014 Dec 5. [http://www.haematologica.org/content/100/4/534.full link to original article] '''contains verified protocol [http://www.haematologica.org/content/haematol/suppl/2015/04/01/haematol.2014.108472.DC1/2014.108472.PULCZYNSKI_SUPPL.pdf in supplement]''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380727/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25480497 PubMed]

==Nordic Regimen, younger patients {{#subobject:e571ce|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:2874b2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380727/ Pulczynski et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}

''This regimen is meant for patients aged 18-65 years.''

====Chemotherapy, A cycles====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 '''of the 1st A cycle only'''
*[[Methotrexate (MTX)]] 5000 mg/m<sup>2</sup> IV once on day 1
*[[Ifosfamide (Ifex)]] 800 mg/m<sup>2</sup> IV once per day on days 2 to 5
*[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup>/day PO on days 2 to 5
*[[Cytarabine liposomal (DepoCyt)]] 50 mg IT once on day 2

====Chemotherapy, B cycles====
*[[Methotrexate (MTX)]] 5000 mg/m<sup>2</sup> IV once on day 1
*[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup>/day PO on days 2 to 5
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Cytarabine liposomal (DepoCyt)]] 50 mg IT once on day 2
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV once per day on days 2 to 5

====Chemotherapy, C cycles====
*[[Dexamethasone (Decadron)]] 20 mg/m<sup>2</sup>/day PO on days 3 to 7
*[[Cytarabine (Cytosar)]] 1500 mg/m<sup>2</sup> IV every 12 hours on days 1 & 2
*[[Vindesine (Eldisine)]] 5 mg IV once on day 1

'''21-day cycle for 6 cycles (A, then B, then C, then A, then B, then C)'''

===References===
# Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli UM. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica. 2015 Apr;100(4):534-40. Epub 2014 Dec 5. [http://www.haematologica.org/content/100/4/534.full link to original article] '''contains verified protocol [http://www.haematologica.org/content/haematol/suppl/2015/04/01/haematol.2014.108472.DC1/2014.108472.PULCZYNSKI_SUPPL.pdf in supplement]''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380727/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25480497 PubMed]

==R-MCP {{#subobject:58966e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-MCP: '''<u>R</u>'''ituximab, '''<u>M</u>'''ethotrexate, '''<u>C</u>'''CNU (Lomustine), '''<u>P</u>'''rocarbazine

===Regimen {{#subobject:6b72ea|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/22/9/2080.long Fritsch et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}

====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV over 90 minutes once per day on days -6, 1, 15, 29
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 4 hours once per day on days 2, 16, 30
*[[Lomustine (Ceenu)]] 110 mg/m<sup>2</sup> PO once on day 2
*[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 2 to 11

====Supportive medications====
*[[Folinic acid (Leucovorin)]] (dose/route not specified) every 6 hours beginning 24 hours after start of MTX infusion, continued for 3 days or until clearance

'''43-day cycle for up to 3 cycles'''

===References===
# Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, Haug S, Ihorst G, Finke J, Illerhaus G. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011 Sep;22(9):2080-5. Epub 2011 Feb 8. [http://annonc.oxfordjournals.org/content/22/9/2080.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21303800 PubMed]

==R-MP {{#subobject:58b4a9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-MP: '''<u>R</u>'''ituximab, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rocarbazine

===Regimen {{#subobject:6ea131|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383936/ Fritsch et al. 2016 (PRIMAIN)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV over 90 minutes once per day on days -6, 1, 15, 29
**Cycles 2 & 3: 375 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 15, 29
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 4 hours once per day on on days 2, 16, 30
*[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 2 to 11

'''42-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Procarbazine_monotherapy|Procarbazine maintenance]]

===References===
# Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017 Apr;31(4):846-852. Epub 2016 Nov 15. [https://www.nature.com/leu/journal/v31/n4/full/leu2016334a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383936/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27843136 PubMed]

==R-MPV {{#subobject:5ca49d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-MPV: '''<u>R</u>'''ituximab, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rocarbazine, '''<u>V</u>'''incristine

===Regimen {{#subobject:ac140a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/25/30/4730.long Shah et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342354/ Omuro et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 500 mg/m<sup>2</sup> IV over 5 hours once on day 1
*[[Methotrexate (MTX)]] 3500 mg/m<sup>2</sup> IV over 2 hours once on day 2
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 7 of odd cycles 
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2.8 mg) IV once on day 2

====Intrathecal chemotherapy====
*''(only described in the Shah et al. 2007 trial)''
*[[Methotrexate (MTX)]] 12 mg IT (via Ommaya) once sometime between day 5 and 12 (for patients with positive CSF cytology)

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 20 to 25 mg every 6 hours for at least 72 hours or until serum MTX level less than 100 nmol/L, beginning 24 hours after IV [[Methotrexate (MTX)]] administration

'''14-day cycle for 5 to 7 cycles'''
====Subsequent treatment====
*Shah et al. 2007: followed in 3 to 5 weeks by [[#Whole_brain_irradiation|whole-brain irradiation]]
*Omuro et al. 2015: [[#Bu.2FTT.2FCy.2C_then_auto_HSCT|Bu/TT/Cy, then autologous hematopoietic stem cell transplant]], after 5 cycles if CR achieved, or after 7 cycles for PR/CR at that time

===References===
# Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007 Oct 20;25(30):4730-5. Erratum in: J Clin Oncol. 2008 Jan 10;26(2):340. [http://jco.ascopubs.org/content/25/30/4730.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17947720 PubMed]
## '''Update:''' Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013 Nov 1;31(31):3971-9. Epub 2013 Oct 7. [http://jco.ascopubs.org/content/31/31/3971.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24101038 PubMed]
# Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015 Feb 26;125(9):1403-10. Epub 2015 Jan 7. [http://www.bloodjournal.org/content/125/9/1403 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342354/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25568347 PubMed]

=Consolidation and/or maintenance after upfront therapy=

==BCNU/TT, then auto HSCT {{#subobject:a7b7ae|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BCNU/TT: '''<u>BCNU</u>''' (Carmustine), '''<u>T</u>'''hio'''<u>T</u>'''epa

===Variant #1 {{#subobject:81ede7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/24/3865.full Illerhaus et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note that the day count starts from the very beginning of treatment.''
====Preceding treatment====
*[[#Methotrexate.2C_then_Cytarabine_.26_Thiotepa|High-dose methotrexate, then Ara-C & Thiotepa]]
====Chemotherapy====
*[[Carmustine (BiCNU)]] 400 mg/m<sup>2</sup> IV once on day 50
*[[Thiotepa (Thioplex)]] 5 mg/kg (route not specified) once per day on days 51 & 52

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|Granulocyte colony-stimulating factor]] starting on day 61, continued until WBC greater than 1 x 10<sup>9</sup>/L for 3 days
*"Standard supportive measures were taken according to institutional guidelines."

'''Stem cells re-infused on day 56'''
====Subsequent treatment====
*[[#Whole_brain_irradiation|Whole-brain irradiation]]

===Variant #2 {{#subobject:769950|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.haematologica.org/content/93/1/147.long Illerhaus et al. 2008]
|style="background-color:#ffffbe"|Pilot, <20 patients
|-
|}
====Preceding treatment====
*[[#Methotrexate.2C_then_Cytarabine_.26_Thiotepa|High-dose methotrexate, then Ara-C & Thiotepa]]
====Chemotherapy====
*[[Carmustine (BiCNU)]] 400 mg/m<sup>2</sup> IV once on day 1
*[[Thiotepa (Thioplex)]] 5 mg/kg (route not specified) twice per day on days 2 & 3

'''Stem cells re-infused on day 7'''

===References===
<!-- Presented in part at the 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10-13, 2005. -->
# Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24. [http://jco.ascopubs.org/content/24/24/3865.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16864853 PubMed]
## '''Update:''' Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol. 2012 Oct;23(10):2670-5. Epub 2012 Apr 3. Erratum in: Ann Oncol. 2015 Mar;26(3):608-11. [http://annonc.oxfordjournals.org/content/23/10/2670.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22473593 PubMed]
# Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008 Jan;93(1):147-8. [http://www.haematologica.org/content/93/1/147.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18166803 PubMed]
## '''Update:''' Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol. 2012 Oct;23(10):2670-5. Epub 2012 Apr 3. Erratum in: Ann Oncol. 2015 Mar;26(3):608-11. [http://annonc.oxfordjournals.org/content/23/10/2670.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22473593 PubMed]
# '''IELSG32:''' Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May;3(5):e217-27. Epub 2016 Apr 6. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27132696 PubMed]
## '''Update:''' Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017 Nov;4(11):e510-e523. Epub 2017 Oct 17. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30174-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29054815 PubMed]

==BEAM, then auto HSCT {{#subobject:c9216e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEAM: '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan

===Variant #1 {{#subobject:bbc83f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html Colombat et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#MVBP|MVBP]] x 2
====Chemotherapy====
*[[Carmustine (BiCNU)]] 300 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 2 to 5 
*[[Cytarabine (Cytosar)]] 100 mg/m<sup>2</sup> IV every 12 hours on days 2 to 5
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day 6

'''Day of transplant is not specified'''
====Subsequent treatment====
*[[#Whole_brain_irradiation|Whole-brain irradiation]]

===Variant #2 {{#subobject:5bf047|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/21/22/4151.long Abrey et al. 2003]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Methotrexate.2C_then_Cytarabine|Methotrexate, then Cytarabine]]
====Chemotherapy====
*[[Carmustine (BiCNU)]] 300 mg/m<sup>2</sup> IV once on day -7
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV every 12 hours on days -6 to -3 
*[[Cytarabine (Cytosar)]] 200 mg/m<sup>2</sup> IV every 12 hours on days -6 to -3
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -2

====Supportive medications====
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC every 12 hours starting on day +1, continuing until ANC greater than 1000/uL for 3 days or greater than 10,000/uL for 1 day

'''Stem cells reinfused on day 0'''

===References===
# Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. [http://jco.ascopubs.org/content/21/22/4151.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14615443 PubMed]
# Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16951691 PubMed]

==Bu/TT, then auto HSCT {{#subobject:e04a91|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Bu/TT: '''<u>Bu</u>'''sulfan, '''<u>T</u>'''hio'''<u>T</u>'''epa

===Regimen {{#subobject:df1bb4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/18/4/665.long Montemurro et al. 2007 (OSHO-53)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Methotrexate_monotherapy_2|High-dose methotrexate]] x 2
====Chemotherapy====
*[[Busulfan (Myleran)]] 4 mg/kg PO four times per day on days −8 to −5
*[[Thiotepa (Thioplex)]] 5 mg/kg IV once per day on days -4 & -3

'''Stem cell re-infusion occurs on day 0'''

===References===
# Montemurro M, Kiefer T, Schüler F, Al-Ali HK, Wolf HH, Herbst R, Haas A, Helke K, Theilig A, Lotze C, Hirt C, Niederwieser D, Schwenke M, Krüger WH, Dölken G. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol. 2007 Apr;18(4):665-71. Epub 2006 Dec 21. [http://annonc.oxfordjournals.org/content/18/4/665.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17185743 PubMed]

==Bu/TT/Cy, then auto HSCT {{#subobject:e04a91|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Bu/TT/Cy: '''<u>Bu</u>'''sulfan, '''<u>T</u>'''hio'''<u>T</u>'''epa, '''<u>Cy</u>'''clophosphamide

===Regimen {{#subobject:df1bb4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342354/ Omuro et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-MPV|R-MPV]]
====Chemotherapy====
*[[Busulfan (Myleran)]] 3.2 mg/kg IV once per day on days −6, −5, and −4
*[[Thiotepa (Thioplex)]] 250 mg/m<sup>2</sup> IV once per day on days −9, −8, and −7
*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg IV once per day on days −3 and −2

'''Stem cell re-infusion occurs on day 0'''

===References===
# Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015 Feb 26;125(9):1403-10. Epub 2015 Jan 7. [http://www.bloodjournal.org/content/125/9/1403 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342354/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25568347 PubMed]

==HiDAC {{#subobject:25959d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
HiDAC: '''<u>Hi</u>'''gh '''<u>D</u>'''ose '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine)
===Regimen {{#subobject:4d5aee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2000.18.17.3144 Abrey et al. 2000]
|style="background-color:#91cf61"|Non-randomized
|-
|[http://jco.ascopubs.org/content/20/24/4643.long DeAngelis et al. 2002 (RTOG 93-10)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Time interval of cycles is not explicitly described and is derived from Table 1 in DeAngelis et al. 2002.''
====Preceding treatment====
*[[#Whole_brain_irradiation|Whole-brain irradiation]] x 45 Gy
====Chemotherapy====
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV over 3 hours once per day on days 1 & 2

'''21-day cycle for 2 cycles'''

===References===
# Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000 Sep;18(17):3144-50. [http://ascopubs.org/doi/10.1200/JCO.2000.18.17.3144 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10963643 PubMed]
## '''Update:''' Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006 Oct 1;24(28):4570-4. [http://ascopubs.org/doi/full/10.1200/JCO.2006.06.6910 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17008697 PubMed]
# '''RTOG 93-10:''' DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002 Dec 15;20(24):4643-8. [http://jco.ascopubs.org/content/20/24/4643.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12488408 PubMed]

==CYVE {{#subobject:b2c919|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CYVE: '''<u>CY</u>'''tarabine, '''<u>VE</u>'''pesid (Etoposide)

===Regimen {{#subobject:4df5e6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753699/ Rubenstein et al. 2013 (CALGB 50202)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#MT-R|MT-R induction]]
====Chemotherapy====
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 2 hours every 12 hours on days 1 to 4 (total dose: 16,000 mg/kg)
*[[Etoposide (Vepesid)]] 10 mg/kg/day IV continuous infusion over 96 hours, started on day 1 (total dose: 40 mg/kg)

'''One course'''

===References===
# Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 Sep 1;31(25):3061-8. Epub 2013 Apr 8 [http://jco.ascopubs.org/content/31/25/3061.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753699/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23569323 PubMed]

==Lomustine, Methotrexate, Procarbazine {{#subobject:7f4fbe|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:156623|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/21/14/2726.long Hoang-Xuan et al. 2003 (EORTC 26952)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment==== 
*[[#Lomustine.2C_Methotrexate.2C_Procarbazine.2C_Methylprednisolone.2C|Lomustine, Methotrexate, Procarbazine, Methylprednisolone induction]]
====Chemotherapy====
*[[Methotrexate (MTX)]] 1000 mg/m<sup>2</sup> IV once on day 1
*[[Lomustine (Ceenu)]] 40 mg/m<sup>2</sup> PO once on day 1
*[[Procarbazine (Matulane)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 7

====Intrathecal component====
*[[Methotrexate (MTX)]] 15 mg IT (admixed with [[Cytarabine (Cytosar)]]) once on day 1
*[[Cytarabine (Cytosar)]] 40 mg IT (admixed with [[Methotrexate (MTX)]]) once on day 1

====Supportive medications====
*[[Folinic acid (Leucovorin)]] 25 mg PO every 6 hours for 3 days, initiated 24 hours after IV [[Methotrexate (MTX)]] administration

'''42-day cycle for 5 cycles'''

===References===
# Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B; European Organization for Research and Treatment of Cancer Brain Tumor Group. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003 Jul 15;21(14):2726-31. [http://jco.ascopubs.org/content/21/14/2726.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12860951 PubMed]

==Methotrexate monotherapy {{#subobject:66ffbb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:f64ee1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940660/ Chamberlain et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: the bounds as described in the paper do not account for the situation where CrCl = 60 mL/min/1.73m<sup>2</sup>.''
====Preceding treatment====
*[[#Methotrexate_.26_Rituximab|High-dose methotrexate & Rituximab]]
====Chemotherapy====
*[[Methotrexate (MTX)]] as follows:
**CrCl greater than 60 mL/min/1.73m<sup>2</sup>: 8000 mg/m<sup>2</sup> IV over 6 hours once on day 1
**CrCl less than 60 mL/min/1.73m<sup>2</sup>: 4000 mg/m<sup>2</sup> IV over 6 hours once on day 1

'''28-day cycle for 4 cycles'''

===Variant #2 {{#subobject:c0f639|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/21/6/1044.long Batchelor et al. 2003 (NABTT 96-07)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Methotrexate_monotherapy_2|High-dose methotrexate induction]]
====Chemotherapy====
*[[Methotrexate (MTX)]] 8000 mg/m<sup>2</sup> IV over 4 hours once on day 1
**The full dose of 8000 mg/m<sup>2</sup> was only given if CrCl was at least 100 mL/min/1.73m<sup>2</sup>. For CrCl less than 100 mL/min/1.73m<sup>2</sup>, the dose was reduced by the percentage reduction below 100. For example, a CrCl of 50 mL/min/1.73m<sup>2</sup> would mandate a 50% dose reduction.

'''28-day cycle for 11 cycles'''

===References===
# Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003 Mar 15;21(6):1044-9. [http://jco.ascopubs.org/content/21/6/1044.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12637469 PubMed]
# Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 2010 Jul;12(7):736-44. [http://neuro-oncology.oxfordjournals.org/content/12/7/736.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940660/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20511181 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext Thiel et al. 2010 (G-PCNSL-SG-1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Whole_brain_irradiation|Whole-brain irradiation]]
|style="background-color:#91cf61"|Inconclusive whether non-inferior
|-
|}
====Preceding treatment====
*Before 2006: [[#Methotrexate_monotherapy_2|High-dose methotrexate]] x 6
*After 2006: [[#Ifosfamide_.26_Methotrexate|High-dose methotrexate & ifosfamide]] x 6

'''No further treatment'''

===References===
# Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20970380 PubMed]
## '''Update: Abstract:''' Agnieszka Korfel, Eckhard Thiel, Peter Martus, Robert Moehle, Frank Griesinger, Michael Rauch, Alexander Roeth, Bernd Hertenstein, Thomas Fischer, Thomas Hundsberger, Hans-Guenther Mergenthaler, Christian Junghanss, Tobias Birnbaum, Lars Fischer, Kristoph Jahnke, Ulrich Herrlinger, Ludwig Plasswilm, Thomas Naegele, Torsten Pietsch, Michael Weller. G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up. J Clin Oncol 32:5s, 2014 (suppl; abstr 8527) [http://meetinglibrary.asco.org/content/129168-144 link to abstract]
## '''Update:''' Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015 Mar 24;84(12):1242-8. Epub 2015 Feb 25. [http://www.neurology.org/content/84/12/1242.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25716362 PubMed]

==Procarbazine monotherapy {{#subobject:37e11d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:13bae4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383936/ Fritsch et al. 2016 (PRIMAIN)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-MP|R-MP]] x 3
====Chemotherapy====
*[[Procarbazine (Matulane)]] 100 mg PO once per day on days 1 to 5

'''28-day cycle for 6 cycles'''

===References===
# Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017 Apr;31(4):846-852. Epub 2016 Nov 15. [https://www.nature.com/leu/journal/v31/n4/full/leu2016334a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383936/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27843136 PubMed]

==Temozolomide monotherapy {{#subobject:5c7608|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:5cf6d6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872318/ Glass et al. 2016 (RTOG 0227)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
====Preceding treatment====
*[[#Whole_brain_irradiation|WB-XRT consolidation]]
====Chemotherapy====
*[[Temozolomide (Temodar)]] as follows:
**Week 14: 200 mg/m<sup>2</sup> PO once per day for 5 days (150 mg/m<sup>2</sup> allowed)
**Weeks 18, 22, 26, 30, 34, 38, 42, 46, 50: 200 mg/m<sup>2</sup> PO once per day for 5 days
**Other weeks: omitted

===Variant #2 {{#subobject:084bc7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380727/ Pulczynski et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Nordic_Regimen.2C_older_patients|Nordic Regimen for older patients]]
====Chemotherapy====
*[[Temozolomide (Temodar)]] 150 mg/m<sup>2</sup>/day PO on days 1 to 5

'''28-day cycles for one year or until relapse/progression'''

===References===
# Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø, Leppä S, Fiirgaard B, Bersvendsen H, Fagerli UM. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica. 2015 Apr;100(4):534-40. Epub 2014 Dec 5. [http://www.haematologica.org/content/100/4/534.full link to original article] '''contains verified protocol [http://www.haematologica.org/content/haematol/suppl/2015/04/01/haematol.2014.108472.DC1/2014.108472.PULCZYNSKI_SUPPL.pdf in supplement]''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380727/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25480497 PubMed]
# Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016 May 10;34(14):1620-5. Epub 2016 Mar 28. [http://jco.ascopubs.org/content/34/14/1620.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872318/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27022122 PubMed]

==Whole brain irradiation {{#subobject:6115dc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 23.4 Gy {{#subobject:a6ae7a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/25/30/4730.long Shah et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-MPV|R-MPV]] x 5 to 7 cycles, with complete response
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 23.4 Gy in 1.80-Gy fractions

===Variant #2, 30 Gy {{#subobject:8ca014|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html Colombat et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#BEAM.2C_then_auto_HSCT|BEAM, then autologous hematopoietic stem cell transplant]], with complete response
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 30 Gy in 1.80-Gy fractions

===Variant #3, 30 Gy + 10 Gy boost {{#subobject:b8264a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html Colombat et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#BEAM.2C_then_auto_HSCT|BEAM, then autologous hematopoietic stem cell transplant]], with partial response
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 30 Gy in 1.80-Gy fractions plus 10 Gy boost to the tumor bed

===Variant #4, 36 Gy {{#subobject:d477fd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872318/ Glass et al. 2016 (RTOG 0227)]
|style="background-color:#91cf61"|Phase I/II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext Ferreri et al. 2016 (IELSG32)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#BCNU.2FTT.2C_then_auto_HSCT|BCNU/TT, then auto HSCT]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''Note: reported efficacy for '''IELSG32''' is based on the 2017 update.''
====Preceding treatment====
*RTOG 0227: [[#MT-R|MT-R induction]]
*IELSG32: [[#CYM|Cytarabine & MTX]] versus [[#Cytarabine.2C_Methotrexate.2C_Rituximab|Cytarabine, MTX, Rituximab]] versus [[#MATRix|MATRix]] induction, with complete response
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 36 Gy as follows:
**'''RTOG 0227:''' 1.20-Gy twice-per-day fractions on weeks 11 to 13
**'''IELSG32:''' 1.80-Gy fractions
====Subsequent treatment====
*RTOG 0227: [[#Temozolomide_monotherapy|Temozolomide consolidation]]

===Variant #5, 36 Gy + 9 Gy boost {{#subobject:d377ed|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61416-1/fulltext Ferreri et al. 2009 (IELSG20)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext Ferreri et al. 2016 (IELSG32)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#BCNU.2FTT.2C_then_auto_HSCT|BCNU/TT, then auto HSCT]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''Note: reported efficacy for '''IELSG32''' is based on the 2017 update.''
====Preceding treatment====
*IELSG20: [[#Methotrexate_monotherapy_2|High-dose methotrexate]] x 4 versus [[#CYM|High-dose methotrexate & cytarabine]] x 4, with any response
*IELSG32: [[#CYM|Cytarabine & MTX]] versus [[#Cytarabine.2C_Methotrexate.2C_Rituximab|Cytarabine, MTX, Rituximab]] versus [[#MATRix|MATRix]] induction, with partial response
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 36 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed

===Variant #6, 40 Gy + 9 Gy boost {{#subobject:d662c5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61416-1/fulltext Ferreri et al. 2009 (IELSG20)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Methotrexate_monotherapy_2|High-dose methotrexate]] x 4 versus [[#CYM|High-dose methotrexate & cytarabine]] x 4, with stable or progressive disease
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 40 Gy in 1.80-Gy fractions plus 9 Gy boost to the tumor bed

===Variant #7, 45 Gy {{#subobject:1475db|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2000.18.17.3144 Abrey et al. 2000]
|style="background-color:#91cf61"|Non-randomized
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/20/24/4643.long DeAngelis et al. 2002 (RTOG 93-10)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/24/24/3865.full Illerhaus et al. 2006]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/25/30/4730.long Shah et al. 2007]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext Thiel et al. 2010 (G-PCNSL-SG-1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|No further treatment]]
|style="background-color:#91cf61"|Inconclusive whether non-inferior
|-
|}
''Note that the day count in '''Illerhaus et al. 2006''' starts from the very beginning of treatment.''
====Preceding treatment====
*Abrey et al. 2000 & RTOG 93-10: [[#MPV|MPV]] x 5
*Illerhaus et al. 2006: [[#BCNU.2FTT.2C_then_auto_HSCT|BCNU/TT, then autologous hematopoietic stem cell transplant]], with complete response
*Shaw et al. 2007: [[#R-MPV|R-MPV]] x 5 to 7 cycles, without complete response
*G-PCNSL-SG-1, before 2006: [[#Methotrexate_monotherapy_2|High-dose methotrexate]] x 6
*G-PCNSL-SG-1, after 2006: [[#Ifosfamide_.26_Methotrexate|High-dose methotrexate & ifosfamide]] x 6
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 45 Gy as follows:
**Illerhaus et al. 2006: 1.00-Gy fractions, starting on day 90
**G-PCNSL-SG-1: 1.50-Gy fractions
**Abrey et al. 2000, RTOG 93-10, Shaw et al. 2007: 1.80-Gy fractions

====Subsequent treatment====
*Abrey et al. 2000 & RTOG 93-10: [[#HiDAC_2|HiDAC consolidation]]

===Variant #8, 50 Gy {{#subobject:b0e47a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/24/3865.full Illerhaus et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note that the day count starts from the very beginning of treatment.''
====Preceding treatment====
*[[#BCNU.2FTT.2C_then_auto_HSCT|BCNU/TT, then autologous hematopoietic stem cell transplant]], with partial response
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 50 Gy in 1.00-Gy fractions, starting on day 90

===References===
# Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000 Sep;18(17):3144-50. [http://ascopubs.org/doi/10.1200/JCO.2000.18.17.3144 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10963643 PubMed]
## '''Update:''' Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006 Oct 1;24(28):4570-4. [http://ascopubs.org/doi/full/10.1200/JCO.2006.06.6910 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17008697 PubMed]
# '''RTOG 93-10:''' DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002 Dec 15;20(24):4643-8. [http://jco.ascopubs.org/content/20/24/4643.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12488408 PubMed]
<!-- Presented in part at the 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10-13, 2005. -->
# Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24. [http://jco.ascopubs.org/content/24/24/3865.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16864853 PubMed]
## '''Update:''' Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol. 2012 Oct;23(10):2670-5. Epub 2012 Apr 3. Erratum in: Ann Oncol. 2015 Mar;26(3):608-11. [http://annonc.oxfordjournals.org/content/23/10/2670.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22473593 PubMed]
# Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16951691 PubMed]
# Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007 Oct 20;25(30):4730-5. Erratum in: J Clin Oncol. 2008 Jan 10;26(2):340. [http://jco.ascopubs.org/content/25/30/4730.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17947720 PubMed]
## '''Update:''' Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013 Nov 1;31(31):3971-9. Epub 2013 Oct 7. [http://jco.ascopubs.org/content/31/31/3971.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24101038 PubMed]
# '''IELSG20:''' Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009 Oct 31;374(9700):1512-20. Epub 2009 Sep 18. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61416-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19767089 PubMed]
# '''G-PCNSL-SG-1:''' Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20970380 PubMed]
## '''Update: Abstract:''' Agnieszka Korfel, Eckhard Thiel, Peter Martus, Robert Moehle, Frank Griesinger, Michael Rauch, Alexander Roeth, Bernd Hertenstein, Thomas Fischer, Thomas Hundsberger, Hans-Guenther Mergenthaler, Christian Junghanss, Tobias Birnbaum, Lars Fischer, Kristoph Jahnke, Ulrich Herrlinger, Ludwig Plasswilm, Thomas Naegele, Torsten Pietsch, Michael Weller. G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up. J Clin Oncol 32:5s, 2014 (suppl; abstr 8527) [http://meetinglibrary.asco.org/content/129168-144 link to abstract]
## '''Update:''' Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015 Mar 24;84(12):1242-8. Epub 2015 Feb 25. [http://www.neurology.org/content/84/12/1242.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25716362 PubMed]
# '''RTOG 0227:''' Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016 May 10;34(14):1620-5. Epub 2016 Mar 28. [http://jco.ascopubs.org/content/34/14/1620.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872318/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27022122 PubMed]
# '''IELSG32:''' Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May;3(5):e217-27. Epub 2016 Apr 6. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)00036-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27132696 PubMed]
## '''Update:''' Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017 Nov;4(11):e510-e523. Epub 2017 Oct 17. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30174-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29054815 PubMed]

=Relapsed or refractory, salvage therapy=

==HiDAC {{#subobject:c36841|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
HiDAC: '''<u>Hi</u>'''gh '''<u>D</u>'''ose '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine)
===Regimen {{#subobject:9c7334|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext Thiel et al. 2010 (G-PCNSL-SG-1)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*Before 2006: Non-response to [[#Methotrexate_monotherapy_2|High-dose methotrexate]] 
*After 2006: Non-response to [[#Ifosfamide_.26_Methotrexate|Methotrexate & Ifosfamide]]
====Chemotherapy====
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV over 3 hours every 12 hours on days 1 & 2

'''21-day cycle for 4 cycles'''

===References===
# Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20970380 PubMed]
## '''Update: Abstract:''' Agnieszka Korfel, Eckhard Thiel, Peter Martus, Robert Moehle, Frank Griesinger, Michael Rauch, Alexander Roeth, Bernd Hertenstein, Thomas Fischer, Thomas Hundsberger, Hans-Guenther Mergenthaler, Christian Junghanss, Tobias Birnbaum, Lars Fischer, Kristoph Jahnke, Ulrich Herrlinger, Ludwig Plasswilm, Thomas Naegele, Torsten Pietsch, Michael Weller. G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up. J Clin Oncol 32:5s, 2014 (suppl; abstr 8527) [http://meetinglibrary.asco.org/content/129168-144 link to abstract]
## '''Update:''' Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015 Mar 24;84(12):1242-8. Epub 2015 Feb 25. [http://www.neurology.org/content/84/12/1242.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25716362 PubMed]

==CYVE {{#subobject:a2d919|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CYVE: '''<u>CY</u>'''tarabine, '''<u>VE</u>'''pesid (Etoposide)

===Variant #1 {{#subobject:b4b13a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/19/3/742.full Soussain et al. 2001]
|style="background-color:#91cf61"|Pilot, >20 pts
|-
|[http://jco.ascopubs.org/content/26/15/2512.long Soussain et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cytarabine (Cytosar)]] as follows:
**2000 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 5
**50 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 2 to 5

'''2 cycles'''
====Subsequent treatment====
*Responders: [[#Bu.2FTT.2FCy.2C_then_auto_HSCT_2|Bu/TT/Cy, then autologous hematopoietic stem cell transplant]]

===Variant #2 {{#subobject:921bc8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html Colombat et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*Non-response to [[#MVBP|MVBP]] x 2
====Chemotherapy====
*[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV every 12 hours on days 1 & 2
*[[Etoposide (Vepesid)]] 150 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''Two courses'''
====Subsequent treatment====
*[[#Whole_brain_irradiation_2|Whole-brain irradiation]]

===References===
# Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. [http://jco.ascopubs.org/content/19/3/742.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11157026 PubMed]
# Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16951691 PubMed]
# Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. [http://jco.ascopubs.org/content/26/15/2512.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18413641 PubMed]

==Ifosfamide & Methotrexate {{#subobject:683c6d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*[[Example orders for High-dose Methotrexate (MTX) & Ifosfamide in lymphoma]]
===Regimen {{#subobject:1c70bc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.springerlink.com/content/550r5617ll610848/ Fischer et al. 2008]
|style="background-color:#ffffbe"|Retrospective
|-
|}
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 1500 to 2000 mg/m<sup>2</sup> IV over 3 hours once per day on days 3 to 5
*[[Methotrexate (MTX)]] 4000 mg/m<sup>2</sup> IV over 4 hours once on day 1

====Supportive medications====
*[[Mesna (Mesnex)]] for prophylaxis of hemorrhagic cystitis
*[[Folinic acid (Leucovorin)]] rescue starting 24 hours after start of [[Methotrexate (MTX)]] infusion
*Sodium bicarbonate via IV fluid or PO routes used for urine alkalinization to maintain urine pH of at least 8
**Check methotrexate levels 24, 48, and 72 hours after completion of methotrexate infusion.

[[Methotrexate (MTX)]] dose adjusted for CrCl less than 100 mL/min/1.73m<sup>2</sup> according to the following formula:
*Dose of methotrexate = (CrCl/100) x 4000 mg/m<sup>2</sup>; the paper did not specify what method was used for calculating CrCl. Patients with CrCl less than 50 mL/min/1.73m<sup>2</sup> were excluded from the study.

'''Up to 8 cycles''' (reference did not list timing/criteria to be used for next cycle of therapy)

===References===
# '''Retrospective:''' Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol. 2009 Feb;88(2):133-9. Epub 2008 Aug 5. [http://www.springerlink.com/content/550r5617ll610848/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18679681 PubMed]

==Whole brain irradiation {{#subobject:49c1e3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:1475db|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext Thiel et al. 2010 (G-PCNSL-SG-1)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*Before 2006: Non-response to [[#Methotrexate_monotherapy_2|high-dose MTX]] x 6 
*After 2006: Non-response to [[#Ifosfamide_.26_Methotrexate|High-dose methotrexate & ifosfamide]] x 6
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 45 Gy in 1.5-Gy fractions

===Variant #2 {{#subobject:d82ebe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html Colombat et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#CYVE_2|CYVE salvage]]
====Radiotherapy====
*[[External_beam_radiotherapy|Whole-brain irradiation]] to 30 Gy in 1.8-Gy fractions plus 10 Gy boost to the tumor bed

===Variant #3 {{#subobject:a2619f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/7/1507.full Nguyen et al. 2005]
|style="background-color:#91cf61"|Phase II
|-
|}

''The authors do not clearly describe a pre-determined dosing protocol but report that the most common fraction size was 1.5 Gy.''
====Radiotherapy====
*Median dose:
**Patients not receiving a boost: 36 Gy (range 28 to 45 Gy)
**Patients receiving a boost: 36 Gy (range 19.6 to 40 Gy) + 10 Gy (range 10 to 21.6 Gy)

===References===
# Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005 Mar 1;23(7):1507-13. [http://jco.ascopubs.org/content/23/7/1507.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15735126 PubMed] 
# Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [https://www.nature.com/bmt/journal/v38/n6/full/1705452a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16951691 PubMed]
# Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70229-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20970380 PubMed]
## '''Update: Abstract:''' Agnieszka Korfel, Eckhard Thiel, Peter Martus, Robert Moehle, Frank Griesinger, Michael Rauch, Alexander Roeth, Bernd Hertenstein, Thomas Fischer, Thomas Hundsberger, Hans-Guenther Mergenthaler, Christian Junghanss, Tobias Birnbaum, Lars Fischer, Kristoph Jahnke, Ulrich Herrlinger, Ludwig Plasswilm, Thomas Naegele, Torsten Pietsch, Michael Weller. G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up. J Clin Oncol 32:5s, 2014 (suppl; abstr 8527) [http://meetinglibrary.asco.org/content/129168-144 link to abstract]
## '''Update:''' Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015 Mar 24;84(12):1242-8. Epub 2015 Feb 25. [http://www.neurology.org/content/84/12/1242.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25716362 PubMed]

=Consolidation after salvage therapy=

==Bu/TT/Cy, then auto HSCT {{#subobject:3f8412|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Bu/TT/Cy: '''<u>Bu</u>'''sulfan, '''<u>T</u>'''hio'''<u>T</u>'''epa, '''<u>Cy</u>'''clophosphamide

===Regimen {{#subobject:ab67a7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/19/3/742.full Soussain et al. 2001]
|style="background-color:#91cf61"|Pilot, >20 pts
|-
|[http://jco.ascopubs.org/content/26/15/2512.long Soussain et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#CYVE_2|CYVE salvage]] x 2
====Preparative regimen====
*[[Busulfan (Myleran)]] as follows:
**Up to 60 years old: 10 mg/kg PO or 8 mg/kg IV once per day on days −6, −5, and −4
**≥60 years old: 6 mg/kg PO or 4.8 mg/kg IV once per day on days −6, −5, and −4
*[[Thiotepa (Thioplex)]] 250 mg/m<sup>2</sup> IV once per day on days −9, −8, and −7
*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg IV once per day on days −3 & −2

====Supportive medications====
*[[Clonazepam (Klonopin)]] 2 mg/day IV from the first day of [[Busulfan (Myleran)]] until completion of [[Busulfan (Myleran)]]

'''Stem cell re-infusion occurs on day 0'''

===References===
# Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. [http://jco.ascopubs.org/content/19/3/742.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11157026 PubMed]
# Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. [http://jco.ascopubs.org/content/26/15/2512.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18413641 PubMed]

=Relapsed or refractory, subsequent lines of therapy=
==Rituximab monotherapy {{#subobject:b1f8c5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:3e2c19|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059144/ Batchelor et al. 2011]
|style="background-color:#ffffbe"|Pilot, <20 pts
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week

'''Up to 8 weeks of treatment'''

===References===
# Batchelor TT, Grossman SA, Mikkelsen T, Ye for, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011 Mar 8;76(10):929-30. [http://www.neurology.org/content/76/10/929.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059144/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21383331 PubMed]

==Temozolomide monotherapy {{#subobject:be70fc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:23777b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360092/ Reni et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Temozolomide (Temodar)]] 150 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''28-day cycles'''

===References===
# Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007 Mar 26;96(6):864-7. Epub 2007 Feb 27. [https://www.nature.com/bjc/journal/v96/n6/full/6603660a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360092/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/17325700 PubMed]

==Temsirolimus monotherapy {{#subobject:021ac0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:0ad4c0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/34/15/1757.full Korfel et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
''This is the dose used in stage 2 of this two-stage protocol.''
====Chemotherapy====
*[[Temsirolimus (Torisel)]] 75 mg IV once per week

'''Continued until progression or intolerance'''

===References===
# Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P. Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. J Clin Oncol. 2016 May 20;34(15):1757-63. Epub 2016 Mar 14. [http://jco.ascopubs.org/content/34/15/1757.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26976424 PubMed]

==Topotecan monotherapy {{#subobject:f51103|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:26ef01|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/17/7/1141.long Fischer et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|[http://link.springer.com/article/10.1007/s11060-007-9464-6/fulltext.html Voloschin et al. 2008]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|}
====Chemotherapy====
*[[Topotecan (Hycamtin)]] 1.5 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5

====Supportive medications====
*Voloschin et al. 2008: [[Ondansetron (Zofran)]] (dose/route not specified) prior to chemotherapy

'''21-day cycle for 6 to 10 cycles'''

===References===
# Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, Korfel A. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006 Jul;17(7):1141-5. Epub 2006 Apr 7. [http://annonc.oxfordjournals.org/content/17/7/1141.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16603598 PubMed]
# Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol. 2008 Jan;86(2):211-5. Epub 2007 Sep 21. [http://link.springer.com/article/10.1007/s11060-007-9464-6/fulltext.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17896078 PubMed]

=Prognosis=

==IELSG Prognostic Scoring System (2003)==
# Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003 Jan 15;21(2):266-72. [http://jco.ascopubs.org/content/21/2/266.longlink to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12525518 PubMed]

[[Category:CNS lymphoma regimens]]
[[Category:Disease-specific pages]]
[[Category:CNS cancers]]
